Caixin Global – Latest China News & Headlines

Home >


CX Tech is Caixin Global's real-time tech news portal, featuring 24-hour news, short-form analysis, and roundups from business and tech media in China.

JD Logistics Takes Pitches from Banks for Planned Hong Kong IPO in 2021
New Rules Derail Mega Livestreaming E-Commerce Deal
Trending in China: Why Are People Queuing Eight Hours and Paying $30 for a Cup of Milk Tea?
Trending in China: Teacher Assaulting Children Raises Question About Role of Volunteers in Education
‘Look, No Hands!’ - AutoX Rolls Out China’s First Self-Driving Fleet Without Safety Drivers
U.S. Firms Deny Selling to China Military, as Washington Prepares New Blacklist
Baker Bros. Advisors Sells ADSs in BeiGene Just Months After Buying Shares
Trending in China: Sharing Students’ Grades Online – The Fine Line Between Motivation and Public Shaming
Tesla Rival Li Auto Plans New Share Sale to Bankroll R&D
Alibaba Logistics Arm Chills with Ethiopian Airlines to Transport Covid-19 Vaccines
U.S. Blacklist of Chinese Tech Firms Continues to Grow
China's Bluetooth Audio Chip King Set For $741m Shanghai IPO
U.S.-Blacklisted Hikvision Zooms in on COVID Tracking Demand Reports First Quarterly Profit of 2020 as Travel Recovers
Xiaomi Raises Nearly $4 Billion Through Sale of Shares and Bonds
Baidu Leads China in AI Patent Applications and Ownership
Trending in China: Now Forbidden on China’s Trains
Chinese Biopharma Firm Pegbio Nets $122m in Pre-IPO Round From YF Capital, Yingke, Others
NEV Makers Nio and Xpeng Keep Revving Up Sales, But Investor Unimpressed
Britain Bans Installation of New Huawei 5G Equipment from September 2021 in Major U-Turn
Chinese Biotech Startup Genecast Bags $149 Million in Series E Funding Round

By Ding Yi / Oct 27, 2020 05:22 PM / Finance

Genecast Biotechnology, a Chinese biotech startup that specializes in second-generation sequencing technology and bioinformatics, has closed its 1 billion yuan ($149 million) series E funding round led by China Structural Reform Fund, the company said in a statement on Monday.

Other investors include Taikang Asset Management, CCB Private Equity Investment Management, Hillhouse Capital’s venture capital unit GL Ventures and China Renaissance, according to the statement.

Genecast Biotechnology will use the proceeds from the financing round to develop new diagnostics products for tumors, accelerate the registration and application of its in vitro diagnostic devices and expand its marketing channels, according to the statement.

Founded in 2014, the Wuxi, Jiangsu province-based company has regional sales and services branches across 12 major cities in China. It has also built ties with nearly 500 top hospitals in China and more than 20 drug makers globally, according the company’s website.

Contact reporter Ding Yi (

Related: Chinese Genomics Company BGI to Provide Ethiopia with Coronavirus Testing Kits Made at African Plant

Share this article
Open WeChat and scan the QR code